ATE538813T1 - Serumthymischer faktor zur behandlung von oxidativem stress bei allergien - Google Patents
Serumthymischer faktor zur behandlung von oxidativem stress bei allergienInfo
- Publication number
- ATE538813T1 ATE538813T1 AT01958548T AT01958548T ATE538813T1 AT E538813 T1 ATE538813 T1 AT E538813T1 AT 01958548 T AT01958548 T AT 01958548T AT 01958548 T AT01958548 T AT 01958548T AT E538813 T1 ATE538813 T1 AT E538813T1
- Authority
- AT
- Austria
- Prior art keywords
- proteins
- factor
- drugs
- lead
- pharmaceutical compositions
- Prior art date
Links
- 230000036542 oxidative stress Effects 0.000 title abstract 3
- 108010003422 Circulating Thymic Factor Proteins 0.000 title abstract 2
- 230000007815 allergy Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 108700020469 14-3-3 Proteins 0.000 abstract 1
- 102000004899 14-3-3 Proteins Human genes 0.000 abstract 1
- 102000003960 Ligases Human genes 0.000 abstract 1
- 108090000364 Ligases Proteins 0.000 abstract 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 abstract 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 abstract 1
- 102000051624 phosphatidylethanolamine binding protein Human genes 0.000 abstract 1
- 108700021017 phosphatidylethanolamine binding protein Proteins 0.000 abstract 1
- 230000006697 redox regulation Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000256943 | 2000-08-28 | ||
| PCT/JP2001/007354 WO2002017965A1 (en) | 2000-08-28 | 2001-08-28 | Medicinal compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE538813T1 true ATE538813T1 (de) | 2012-01-15 |
Family
ID=18745480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01958548T ATE538813T1 (de) | 2000-08-28 | 2001-08-28 | Serumthymischer faktor zur behandlung von oxidativem stress bei allergien |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20030186839A1 (de) |
| EP (1) | EP1316315B1 (de) |
| JP (1) | JP5035582B2 (de) |
| AT (1) | ATE538813T1 (de) |
| AU (1) | AU2001280199A1 (de) |
| WO (1) | WO2002017965A1 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8003345B2 (en) * | 2002-11-10 | 2011-08-23 | Institute Of Cell Biophysics Russian Academy Of Sciences | Antioxidant pharmaceutical compound, method for producing polypeptide and method of cure |
| DE60304989T2 (de) | 2003-02-18 | 2007-03-29 | Clinique La Prairie Research S.A. | Zusammensetzungen enthaltend fötales Hämoglobin und bakterielles Endotoxin und fakultativ zusätzliche fötale Leberkomponenten |
| WO2012075911A1 (zh) * | 2010-12-06 | 2012-06-14 | Li Jianyuan | 重组人prx-6蛋白在治疗烧烫伤和/或角膜损伤中的用途 |
| JP5804592B2 (ja) * | 2011-04-22 | 2015-11-04 | 独立行政法人国立高等専門学校機構 | 抗アレルギーのための医薬品組成物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4680276A (en) * | 1977-05-25 | 1987-07-14 | Institut National De La Sante Et De La Recherche Medicale | Metal polypeptides |
| JPS5852225A (ja) * | 1981-09-22 | 1983-03-28 | Mitsui Pharmaceut Inc | 脱髄疾患治療剤 |
| US5352665A (en) * | 1987-11-24 | 1994-10-04 | Mitsui Toatsu Chemicals, Incorporated | Method of treating disease caused by the infection of virus |
| US5288706A (en) * | 1987-12-25 | 1994-02-22 | Mitsui Toatsu Chemicals, Incorporated | Medicament for prevention and remedy of diseases of the pancreas and others |
| US5591446A (en) * | 1989-04-04 | 1997-01-07 | Beiersdorf, A.G. | Methods and agents for the prophylaxis of atopy |
| JP3751986B2 (ja) * | 1994-06-21 | 2006-03-08 | 英良 横沢 | 医薬組成物 |
| JP3717955B2 (ja) * | 1994-07-14 | 2005-11-16 | 道夫 藤原 | 医薬組成物 |
| JP3784847B2 (ja) * | 1994-09-26 | 2006-06-14 | 道夫 藤原 | 肝・胆管系疾患予防・治療剤 |
| JP3728515B2 (ja) * | 1994-10-24 | 2005-12-21 | 泰信 吉開 | 医薬組成物 |
| JP2000103743A (ja) * | 1998-09-29 | 2000-04-11 | Jiyunji Yodoi | チオレドキシン活性を有するファミリーに属するポリペプチド類を含有する食品、化粧品及び医薬 |
-
2001
- 2001-08-28 AT AT01958548T patent/ATE538813T1/de active
- 2001-08-28 US US10/362,218 patent/US20030186839A1/en not_active Abandoned
- 2001-08-28 JP JP2002522938A patent/JP5035582B2/ja not_active Expired - Fee Related
- 2001-08-28 WO PCT/JP2001/007354 patent/WO2002017965A1/ja not_active Ceased
- 2001-08-28 EP EP01958548A patent/EP1316315B1/de not_active Expired - Lifetime
- 2001-08-28 AU AU2001280199A patent/AU2001280199A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2001280199A1 (en) | 2002-03-13 |
| EP1316315B1 (de) | 2011-12-28 |
| EP1316315A1 (de) | 2003-06-04 |
| EP1316315A4 (de) | 2005-06-08 |
| JPWO2002017965A1 (ja) | 2004-01-15 |
| JP5035582B2 (ja) | 2012-09-26 |
| WO2002017965A1 (en) | 2002-03-07 |
| US20030186839A1 (en) | 2003-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | Curcumin modulates the crosstalk between macrophages and bone mesenchymal stem cells to ameliorate osteogenesis | |
| NZ319090A (en) | (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors | |
| ATE169304T1 (de) | Biologisch aktive peptide aus funktionellen domaenen des bakteriziden/ die permeabilitaet erhoehenden proteins und ihre verwendung | |
| JO2373B1 (en) | W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors | |
| WO2003099771A3 (en) | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | |
| ATE71629T1 (de) | Methylenphosphonalkylphosphinate, pharmazeutische zubereitungen und verfahren zur behandlung abnormalen kalzium- und phosphat-stoffwechsels. | |
| ATE439833T1 (de) | Pharmazeutische zubereitung enthaltend ein catechin, ascorbinsäure, prolin und lysin zur behandlung von neoplastischen krankheiten | |
| ATE538813T1 (de) | Serumthymischer faktor zur behandlung von oxidativem stress bei allergien | |
| DE60100500D1 (de) | Suspension enthaltend ein epi-hne protein, verfahren zu ihrer herstellung, daraus hergestelltes trockenpulveraerosol, arzneimittelzusammensetzungen enthaltend diese suspension oder dieses aerosol und ihre verwendungen | |
| DE69816047D1 (en) | (methylsulfonyl)phenyl-2-(5h)-furanone mit sauerstoff-bindung als cox-2-hemmer | |
| TW200719908A (en) | Dermatologic use of milk proteins | |
| EP1080724A4 (de) | Zusammenstellung die die mpt-aktivität mindert | |
| Hayann et al. | A nontoxic strontium nanoparticle that holds the potential to act upon osteocompetent cells: an in vitro and in vivo characterization | |
| ATE310828T1 (de) | Implantat und vektor zur behandlung von erworbenen krankheiten | |
| ATE151774T1 (de) | Cyclopentanperhydrophenanthren-17-beta-(3-furyl - 3-derivate und pharmazeutische präparate davon, zur behandlung von kardiovaskulär-erkrankungen | |
| DE69333351D1 (de) | Rekombinante lipase aus hundemagen und pharmazeutische zusammensetzungen | |
| DE69816808D1 (de) | Somatostatin agoniste zur reduzierung von körpergewicht | |
| ATE312179T1 (de) | Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose | |
| PT811068E (pt) | Variantes da adnase i humana | |
| ATE512981T1 (de) | Identifizierung von ses-3 (spr-5) aus c. elegans sowie dessen verwendungen | |
| ATE317905T1 (de) | Arzneimittel enthaltend wenigstens einen teil des ul84-proteins des cytomegalovirus, verwendung von polypeptiden entsprechend der aminosäuresequenz des ul84-proteins und verfahren zur einführung von ul84 in zielzellen | |
| ATE364081T1 (de) | Identifizierung von ses-1 aus c. elegans sowie dessen verwendung | |
| WO2001066740A3 (en) | Compositions and methods for the treatment of immune related diseases | |
| Yang et al. | Lactoferrin constitutively enhances differentiation of osteoblastic MC3T3-E1 cells in vitro | |
| WO2001016319A3 (en) | Compositions and methods for the treatment of immune related diseases |